Loading…
Association between duration of tirofiban therapy before percutaneous intervention and tissue level perfusion (a TACTICS-TIMI 18 substudy)
In the setting of acute coronary syndromes, thrombotic embolization and activation of platelets with release of vasoconstrictors into the downstream microvasculature may occur before cardiac catheterization. In the Treat Angina with tirofiban and determine Cost of Therapy with an Invasive or Conserv...
Saved in:
| Published in: | The American journal of cardiology 2004-08, Vol.94 (4), p.492-494 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c418t-22690e9a717b3e22e8ef5560ba892931ce817e1654eff54605969cca8f57c953 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c418t-22690e9a717b3e22e8ef5560ba892931ce817e1654eff54605969cca8f57c953 |
| container_end_page | 494 |
| container_issue | 4 |
| container_start_page | 492 |
| container_title | The American journal of cardiology |
| container_volume | 94 |
| creator | Gibson, C.Michael Singh, Kanwar P. Murphy, Sabina A. DiBattiste, Peter M. Demopoulos, Laura A. Cannon, Christopher P. Braunwald, Eugene |
| description | In the setting of acute coronary syndromes, thrombotic embolization and activation of platelets with release of vasoconstrictors into the downstream microvasculature may occur before cardiac catheterization. In the Treat Angina with tirofiban and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis In Myocardial Infarction 18 (TACTICS-TIMI 18) trial angiographic substudy, a shorter duration of tirofiban infusion before percutaneous coronary intervention was associated with impaired myocardial perfusion before and after intervention. |
| doi_str_mv | 10.1016/j.amjcard.2004.04.066 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66809153</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0002914904007179</els_id><sourcerecordid>743004781</sourcerecordid><originalsourceid>FETCH-LOGICAL-c418t-22690e9a717b3e22e8ef5560ba892931ce817e1654eff54605969cca8f57c953</originalsourceid><addsrcrecordid>eNqFkV2r1DAQhosonvXoT1CCoOhF16TdpM3VYVn8WDjihb0PaTrBlG6y5mNl_4K_2tQWDngjDIRknncyM29RvCR4SzBhH8atPI1K-mFbYbzbzsHYo2JD2oaXhJP6cbHBGFclJzt-UzwLYcxXQih7WtwQWleU182m-L0PwSkjo3EW9RB_AVg0JL88OI2i8U6bXloUf4CX52umtPOAzuBVitKCSwEZG8FfwP5VSTtkWQgJ0AQXmGZUpzCn3knU7Q_d8fC97I5fj4i0KKQ-xDRc3z8vnmg5BXixnrdF9-ljd_hS3n_7fDzs70u1I20sq4pxDFw2pOlrqCpoQVPKcC9bXvGaKGhJA4TRHWhNdwxTzrhSstW0UZzWt8XbpezZu58JQhQnExRM0zKKYKzFPC8og6__AUeXvM2tiarGNWUMswzRBVLeheBBi7M3J-mvgmAxGyVGsRolZqPEHGzWvVqLp_4Ew4NqdSYDb1ZABiUn7aVVJjxw-XPKW5K5u4WDvLKLAS-CMmAVDMaDimJw5j-t_AFO6bRM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>230356606</pqid></control><display><type>article</type><title>Association between duration of tirofiban therapy before percutaneous intervention and tissue level perfusion (a TACTICS-TIMI 18 substudy)</title><source>ScienceDirect Journals</source><creator>Gibson, C.Michael ; Singh, Kanwar P. ; Murphy, Sabina A. ; DiBattiste, Peter M. ; Demopoulos, Laura A. ; Cannon, Christopher P. ; Braunwald, Eugene</creator><creatorcontrib>Gibson, C.Michael ; Singh, Kanwar P. ; Murphy, Sabina A. ; DiBattiste, Peter M. ; Demopoulos, Laura A. ; Cannon, Christopher P. ; Braunwald, Eugene ; TIMI Study Group</creatorcontrib><description>In the setting of acute coronary syndromes, thrombotic embolization and activation of platelets with release of vasoconstrictors into the downstream microvasculature may occur before cardiac catheterization. In the Treat Angina with tirofiban and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis In Myocardial Infarction 18 (TACTICS-TIMI 18) trial angiographic substudy, a shorter duration of tirofiban infusion before percutaneous coronary intervention was associated with impaired myocardial perfusion before and after intervention.</description><identifier>ISSN: 0002-9149</identifier><identifier>EISSN: 1879-1913</identifier><identifier>DOI: 10.1016/j.amjcard.2004.04.066</identifier><identifier>PMID: 15325937</identifier><identifier>CODEN: AJCDAG</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Aged ; Angina, Unstable - diagnostic imaging ; Angina, Unstable - drug therapy ; Angina, Unstable - economics ; Angioplasty, Balloon, Coronary - economics ; Biological and medical sciences ; Cardiac Catheterization - economics ; Cardiology. Vascular system ; Cardiovascular disease ; Catheters ; Coronary Angiography - economics ; Coronary vessels ; Cost-Benefit Analysis ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Drug therapy ; Female ; Heart ; Humans ; Male ; Medical sciences ; Medical treatment ; Microcirculation - drug effects ; Middle Aged ; Myocardial Infarction - diagnostic imaging ; Myocardial Infarction - drug therapy ; Myocardial Infarction - economics ; Myocardial Reperfusion Injury - diagnostic imaging ; Myocardial Reperfusion Injury - economics ; Myocardial Reperfusion Injury - prevention & control ; Platelet Aggregation Inhibitors - administration & dosage ; Platelet Aggregation Inhibitors - adverse effects ; Platelet Aggregation Inhibitors - economics ; Premedication - economics ; Thrombolytic Therapy - economics ; Treatment Outcome ; Tyrosine - administration & dosage ; Tyrosine - adverse effects ; Tyrosine - analogs & derivatives ; Tyrosine - economics</subject><ispartof>The American journal of cardiology, 2004-08, Vol.94 (4), p.492-494</ispartof><rights>2004 Excerpta Medica Inc.</rights><rights>2004 INIST-CNRS</rights><rights>Copyright Elsevier Sequoia S.A. Aug 15, 2004</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c418t-22690e9a717b3e22e8ef5560ba892931ce817e1654eff54605969cca8f57c953</citedby><cites>FETCH-LOGICAL-c418t-22690e9a717b3e22e8ef5560ba892931ce817e1654eff54605969cca8f57c953</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16065981$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15325937$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gibson, C.Michael</creatorcontrib><creatorcontrib>Singh, Kanwar P.</creatorcontrib><creatorcontrib>Murphy, Sabina A.</creatorcontrib><creatorcontrib>DiBattiste, Peter M.</creatorcontrib><creatorcontrib>Demopoulos, Laura A.</creatorcontrib><creatorcontrib>Cannon, Christopher P.</creatorcontrib><creatorcontrib>Braunwald, Eugene</creatorcontrib><creatorcontrib>TIMI Study Group</creatorcontrib><title>Association between duration of tirofiban therapy before percutaneous intervention and tissue level perfusion (a TACTICS-TIMI 18 substudy)</title><title>The American journal of cardiology</title><addtitle>Am J Cardiol</addtitle><description>In the setting of acute coronary syndromes, thrombotic embolization and activation of platelets with release of vasoconstrictors into the downstream microvasculature may occur before cardiac catheterization. In the Treat Angina with tirofiban and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis In Myocardial Infarction 18 (TACTICS-TIMI 18) trial angiographic substudy, a shorter duration of tirofiban infusion before percutaneous coronary intervention was associated with impaired myocardial perfusion before and after intervention.</description><subject>Aged</subject><subject>Angina, Unstable - diagnostic imaging</subject><subject>Angina, Unstable - drug therapy</subject><subject>Angina, Unstable - economics</subject><subject>Angioplasty, Balloon, Coronary - economics</subject><subject>Biological and medical sciences</subject><subject>Cardiac Catheterization - economics</subject><subject>Cardiology. Vascular system</subject><subject>Cardiovascular disease</subject><subject>Catheters</subject><subject>Coronary Angiography - economics</subject><subject>Coronary vessels</subject><subject>Cost-Benefit Analysis</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Administration Schedule</subject><subject>Drug therapy</subject><subject>Female</subject><subject>Heart</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Medical treatment</subject><subject>Microcirculation - drug effects</subject><subject>Middle Aged</subject><subject>Myocardial Infarction - diagnostic imaging</subject><subject>Myocardial Infarction - drug therapy</subject><subject>Myocardial Infarction - economics</subject><subject>Myocardial Reperfusion Injury - diagnostic imaging</subject><subject>Myocardial Reperfusion Injury - economics</subject><subject>Myocardial Reperfusion Injury - prevention & control</subject><subject>Platelet Aggregation Inhibitors - administration & dosage</subject><subject>Platelet Aggregation Inhibitors - adverse effects</subject><subject>Platelet Aggregation Inhibitors - economics</subject><subject>Premedication - economics</subject><subject>Thrombolytic Therapy - economics</subject><subject>Treatment Outcome</subject><subject>Tyrosine - administration & dosage</subject><subject>Tyrosine - adverse effects</subject><subject>Tyrosine - analogs & derivatives</subject><subject>Tyrosine - economics</subject><issn>0002-9149</issn><issn>1879-1913</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><recordid>eNqFkV2r1DAQhosonvXoT1CCoOhF16TdpM3VYVn8WDjihb0PaTrBlG6y5mNl_4K_2tQWDngjDIRknncyM29RvCR4SzBhH8atPI1K-mFbYbzbzsHYo2JD2oaXhJP6cbHBGFclJzt-UzwLYcxXQih7WtwQWleU182m-L0PwSkjo3EW9RB_AVg0JL88OI2i8U6bXloUf4CX52umtPOAzuBVitKCSwEZG8FfwP5VSTtkWQgJ0AQXmGZUpzCn3knU7Q_d8fC97I5fj4i0KKQ-xDRc3z8vnmg5BXixnrdF9-ljd_hS3n_7fDzs70u1I20sq4pxDFw2pOlrqCpoQVPKcC9bXvGaKGhJA4TRHWhNdwxTzrhSstW0UZzWt8XbpezZu58JQhQnExRM0zKKYKzFPC8og6__AUeXvM2tiarGNWUMswzRBVLeheBBi7M3J-mvgmAxGyVGsRolZqPEHGzWvVqLp_4Ew4NqdSYDb1ZABiUn7aVVJjxw-XPKW5K5u4WDvLKLAS-CMmAVDMaDimJw5j-t_AFO6bRM</recordid><startdate>20040815</startdate><enddate>20040815</enddate><creator>Gibson, C.Michael</creator><creator>Singh, Kanwar P.</creator><creator>Murphy, Sabina A.</creator><creator>DiBattiste, Peter M.</creator><creator>Demopoulos, Laura A.</creator><creator>Cannon, Christopher P.</creator><creator>Braunwald, Eugene</creator><general>Elsevier Inc</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TS</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>M7Z</scope><scope>NAPCQ</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20040815</creationdate><title>Association between duration of tirofiban therapy before percutaneous intervention and tissue level perfusion (a TACTICS-TIMI 18 substudy)</title><author>Gibson, C.Michael ; Singh, Kanwar P. ; Murphy, Sabina A. ; DiBattiste, Peter M. ; Demopoulos, Laura A. ; Cannon, Christopher P. ; Braunwald, Eugene</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c418t-22690e9a717b3e22e8ef5560ba892931ce817e1654eff54605969cca8f57c953</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Aged</topic><topic>Angina, Unstable - diagnostic imaging</topic><topic>Angina, Unstable - drug therapy</topic><topic>Angina, Unstable - economics</topic><topic>Angioplasty, Balloon, Coronary - economics</topic><topic>Biological and medical sciences</topic><topic>Cardiac Catheterization - economics</topic><topic>Cardiology. Vascular system</topic><topic>Cardiovascular disease</topic><topic>Catheters</topic><topic>Coronary Angiography - economics</topic><topic>Coronary vessels</topic><topic>Cost-Benefit Analysis</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Administration Schedule</topic><topic>Drug therapy</topic><topic>Female</topic><topic>Heart</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Medical treatment</topic><topic>Microcirculation - drug effects</topic><topic>Middle Aged</topic><topic>Myocardial Infarction - diagnostic imaging</topic><topic>Myocardial Infarction - drug therapy</topic><topic>Myocardial Infarction - economics</topic><topic>Myocardial Reperfusion Injury - diagnostic imaging</topic><topic>Myocardial Reperfusion Injury - economics</topic><topic>Myocardial Reperfusion Injury - prevention & control</topic><topic>Platelet Aggregation Inhibitors - administration & dosage</topic><topic>Platelet Aggregation Inhibitors - adverse effects</topic><topic>Platelet Aggregation Inhibitors - economics</topic><topic>Premedication - economics</topic><topic>Thrombolytic Therapy - economics</topic><topic>Treatment Outcome</topic><topic>Tyrosine - administration & dosage</topic><topic>Tyrosine - adverse effects</topic><topic>Tyrosine - analogs & derivatives</topic><topic>Tyrosine - economics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gibson, C.Michael</creatorcontrib><creatorcontrib>Singh, Kanwar P.</creatorcontrib><creatorcontrib>Murphy, Sabina A.</creatorcontrib><creatorcontrib>DiBattiste, Peter M.</creatorcontrib><creatorcontrib>Demopoulos, Laura A.</creatorcontrib><creatorcontrib>Cannon, Christopher P.</creatorcontrib><creatorcontrib>Braunwald, Eugene</creatorcontrib><creatorcontrib>TIMI Study Group</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Physical Education Index</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biochemistry Abstracts 1</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>The American journal of cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gibson, C.Michael</au><au>Singh, Kanwar P.</au><au>Murphy, Sabina A.</au><au>DiBattiste, Peter M.</au><au>Demopoulos, Laura A.</au><au>Cannon, Christopher P.</au><au>Braunwald, Eugene</au><aucorp>TIMI Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Association between duration of tirofiban therapy before percutaneous intervention and tissue level perfusion (a TACTICS-TIMI 18 substudy)</atitle><jtitle>The American journal of cardiology</jtitle><addtitle>Am J Cardiol</addtitle><date>2004-08-15</date><risdate>2004</risdate><volume>94</volume><issue>4</issue><spage>492</spage><epage>494</epage><pages>492-494</pages><issn>0002-9149</issn><eissn>1879-1913</eissn><coden>AJCDAG</coden><abstract>In the setting of acute coronary syndromes, thrombotic embolization and activation of platelets with release of vasoconstrictors into the downstream microvasculature may occur before cardiac catheterization. In the Treat Angina with tirofiban and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis In Myocardial Infarction 18 (TACTICS-TIMI 18) trial angiographic substudy, a shorter duration of tirofiban infusion before percutaneous coronary intervention was associated with impaired myocardial perfusion before and after intervention.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>15325937</pmid><doi>10.1016/j.amjcard.2004.04.066</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9149 |
| ispartof | The American journal of cardiology, 2004-08, Vol.94 (4), p.492-494 |
| issn | 0002-9149 1879-1913 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_66809153 |
| source | ScienceDirect Journals |
| subjects | Aged Angina, Unstable - diagnostic imaging Angina, Unstable - drug therapy Angina, Unstable - economics Angioplasty, Balloon, Coronary - economics Biological and medical sciences Cardiac Catheterization - economics Cardiology. Vascular system Cardiovascular disease Catheters Coronary Angiography - economics Coronary vessels Cost-Benefit Analysis Dose-Response Relationship, Drug Drug Administration Schedule Drug therapy Female Heart Humans Male Medical sciences Medical treatment Microcirculation - drug effects Middle Aged Myocardial Infarction - diagnostic imaging Myocardial Infarction - drug therapy Myocardial Infarction - economics Myocardial Reperfusion Injury - diagnostic imaging Myocardial Reperfusion Injury - economics Myocardial Reperfusion Injury - prevention & control Platelet Aggregation Inhibitors - administration & dosage Platelet Aggregation Inhibitors - adverse effects Platelet Aggregation Inhibitors - economics Premedication - economics Thrombolytic Therapy - economics Treatment Outcome Tyrosine - administration & dosage Tyrosine - adverse effects Tyrosine - analogs & derivatives Tyrosine - economics |
| title | Association between duration of tirofiban therapy before percutaneous intervention and tissue level perfusion (a TACTICS-TIMI 18 substudy) |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T00%3A27%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Association%20between%20duration%20of%20tirofiban%20therapy%20before%20percutaneous%20intervention%20and%20tissue%20level%20perfusion%20(a%20TACTICS-TIMI%2018%20substudy)&rft.jtitle=The%20American%20journal%20of%20cardiology&rft.au=Gibson,%20C.Michael&rft.aucorp=TIMI%20Study%20Group&rft.date=2004-08-15&rft.volume=94&rft.issue=4&rft.spage=492&rft.epage=494&rft.pages=492-494&rft.issn=0002-9149&rft.eissn=1879-1913&rft.coden=AJCDAG&rft_id=info:doi/10.1016/j.amjcard.2004.04.066&rft_dat=%3Cproquest_cross%3E743004781%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c418t-22690e9a717b3e22e8ef5560ba892931ce817e1654eff54605969cca8f57c953%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=230356606&rft_id=info:pmid/15325937&rfr_iscdi=true |